Holen Sie sich die Stockscreener-App
185.67
0.18%
0.34
Handel nachbörslich:
185.51
-0.16
-0.09%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million - The Motley Fool
AstraZeneca gets FDA nod for new hypertension drug Baxfendy - MSN
AstraZeneca targets year end for COVID-19 vaccine - Edition.mv
AstraZeneca plc stock (GB0009895292): CARES phase 3 data spotlight subgroup benefit after missed end - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): FDA approval for Imfinzi in early bladder cancer adds to US on - AD HOC NEWS
AstraZeneca plc stock (GB0009895292): London-listed pharma group in focus after new CelLBxHealth par - AD HOC NEWS
ASCO26: AstraZeneca’s light chain amyloidosis shows subgroup benefit after Phase III trial - Clinical Trials Arena
CSPC Pharmaceutical receives $1.2 billion upfront payment from AstraZeneca - marketscreener.com
US bank sees positive risk-reward for AstraZeneca ahead of pivotal heart drug trial - Proactive financial news
AstraZeneca highlights data insights from Cares clinical programme - London South East
WINNERS & LOSERS: CelLBxHealth jumps on AstraZeneca partnership - marketscreener.com
CelLBxHealth shares jump on partnership with AstraZeneca - London South East
AstraZeneca's Imfinzi Gets US FDA Nod for Bladder Cancer Combo Therapy - Yahoo Finance UK
CelLBxHealth secures AstraZeneca agreement to provide circulating tumour cell analytics services (CLBX) - Yahoo Finance UK
CelLBxHealth rises 33% after signing AstraZeneca deal - Share Talk
Astrazeneca Obtains US Approval for Imfinzi-based Bladder Cancer Combination Therapy - marketscreener.com
CelLBxHealth shares jump 36% after master services agreement with AstraZeneca - Proactive financial news
Astrazeneca's Imfinzi receives green light from US FDA - Sharecast.com
CelLBxHealth PLC Enters Master Services Agreement With AstraZeneca PLC - marketscreener.com
AstraZeneca’s Imfinzi Plus BCG Approved By FDA For High-risk Bladder Cancer - DirectorsTalk Interviews
CellBxHealth enters master services agreement with AstraZeneca - marketscreener.com
AstraZeneca says Imfinzi approved in US for early bladder cancer - marketscreener.com
AstraZeneca (AZN) withdraws listing for 1.200% Notes due 2026 from NYSE - Stock Titan
AstraZeneca's Durvalumab Approved by FDA in Combination With BCG for Bladder Cancer - marketscreener.com
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology
AstraZeneca PLC stock (US6549022043): FDA extends review for key breast cancer drug as London shares - AD HOC NEWS
ASTRAZENECA : Deutsche Bank keeps a Sell rating - marketscreener.com
PLATINUM INVESTMENT MANAGEMENT LTD's AstraZeneca PLC(AZN) Holding History - GuruFocus
AZN Stock Quote Price and Forecast - CNN
Why Are AstraZeneca, GSK and Hikma Lifting FTSE 100 Focus? - Kalkine Media
Expert View: Greencore, Autotrader, Watkin Jones, and Astrazeneca - Citywire
AstraZeneca PLC stock (US6549022043): FDA extends camizestrant review as investors weigh oncology mo - AD HOC NEWS
AstraZeneca plc stock (GB0009895292): FDA extends camizestrant review - AD HOC NEWS
FDA delays decision on AstraZeneca breast cancer pill - BioPharma Dive
AstraZeneca says FDA has delayed review of breast cancer therapy camizestrant - Seeking Alpha
FDA Delays AstraZeneca's Breast Cancer Drug Review: What to Know - PharmTech.com
AstraZeneca PLC stock (US6549022043): oncology pipeline, Obesity franchise and US market focus in th - AD HOC NEWS
FDA extends review period for AstraZeneca’s camizestrant breast cancer application - Investing.com India
AstraZeneca (AZN) sees FDA delay but EMA backs camizestrant combo - Stock Titan
Why Are AstraZeneca HSBC And Diageo Trending - Kalkine Media
AstraZeneca PLC ADR Dividends – BCBA:AZN.CI - TradingView
US FDA pushes back decision on Astrazeneca's camizestrant - Sharecast.com
US regulator delays decision on AstraZeneca cancer drug - Financial Times
AstraZeneca says FDA extends breast cancer drug review period - London South East
US FDA extends review of AstraZeneca’s experimental breast cancer pill - Reuters
FTSE 100: AstraZeneca (LSE:AZN) Faces Fresh Market Spotlight - Kalkine Media
US FDA decision date extended for SERENA-6 filing of camizestrant to enable review of additional data - AstraZeneca
AstraZeneca Unit Keeps Cancer Therapy IP Despite Stada Jab - Law360
Astrazeneca Pharma India March-quarter PAT 448.8 million rupees - marketscreener.com
AstraZeneca breast cancer drug camizestrant recommended for EU approval - Investing.com
Datroway extends survival in TNBC as AstraZeneca (NYSE: AZN) gains US ok - Stock Titan
AstraZeneca's Buy Rating Reiterated as BofA Notes 'Busy' Pipeline Path; Estimates Revised - marketscreener.com
CHMP backs AstraZeneca (AZN) and Daiichi Sankyo’s Enhertu for HER2‑positive solid tumours in EU - Stock Titan
AstraZeneca plc stock (GB0009895292): oncology approvals and home-market context for UK investors - AD HOC NEWS
AstraZeneca (AZN) gets CHMP backing for camizestrant in ESR1-mutated breast cancer - Stock Titan
Oncology Medicine Development Keeps AstraZeneca Within FTSE 350 - Kalkine Media
AstraZeneca (LSE:AZN) Draws Market Focus as Share Momentum Moderates - Kalkine Media
AstraZeneca PLC stock (US6549022043): cancer portfolio and pipeline in focus after latest oncology d - AD HOC NEWS
AstraZeneca PLC stock (US6549022043): cancer pipeline and diabetes deal keep investors watching - AD HOC NEWS
EU panel backs AstraZeneca breast cancer drug camizestrant By Investing.com - Investing.com Nigeria
AstraZeneca's Enhertu Recommended For EU Approval In HER2-positive Solid Tumours - DirectorsTalk Interviews
AstraZeneca reports Enhertu recommended in EU for HER2+ solid tumours - marketscreener.com
AstraZeneca says Datroway approved in US for 1L triple-negative BC - marketscreener.com
Sir Pascal Soriot: Veterinary Scientist, Pharmaceutical Transformer, and Executive Director and CEO of AstraZeneca - BBN Times
AstraZeneca plc stock (GB0009895292): FDA approval for Datroway puts oncology pipeline in the spotli - AD HOC NEWS
AstraZeneca Maintains FTSE Presence Through Oncology and Global Healthcare - Kalkine Media
AstraZeneca, Daiichi Sankyo’s Datroway receives FDA approval for TNBC - Pharmaceutical Technology
AstraZeneca PLC (AZN) Stock Analysis: Strong Buy Ratings And A 20% Upside Potential - DirectorsTalk Interviews
Phillips Wealth Planners LLC's AstraZeneca PLC(AZN) Holding History - GuruFocus
AstraZeneca stock (US6549022043): New drug and earnings updates keep investors focused - AD HOC NEWS
0.81%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):